RXRX - Recursion Pharmaceuticals: Unprecedented Scale

2024-06-17 10:53:46 ET

Summary

• Recursion Pharmaceuticals is an AI-enabled drug discovery company, differentiated by its scale and focus on understanding biology.
• The company has a broad pipeline across various therapeutic areas and strategic partnerships with biopharmaceutical companies.
• While Recursion is probably the best positioned AI drug discovery company, the stock could pull back if AI hype fades.
• Recursion could benefit from a series of clinical data in coming quarters though.

Recursion Pharmaceuticals ( RXRX ) is a drug discovery company that is leveraging the power of artificial intelligence to try and bring drugs to market more efficiently. While there are a number of companies pursuing a similar strategy, Recursion is differentiated by its holistic approach and the scale at which it is operating. This is somewhat risky given the cost involved and the fact that it is still an unproven approach. It could help to address the declining returns on R&D that the biopharma industry is facing though, creating enormous value for shareholders....

For further details see: